Abstract:
Viral infections are a major cause of severe, fatal diseases worldwide. Recently, these infections have increased due to demanding contextual circumstances, such as environmental changes, increased migration of people and product distribution, rapid demographic changes, and outbreaks of novel viruses, including the COVID-19 outbreak. Internal variables that influence viral immunity have received attention along with these external causes to avert such novel viral outbreaks. The gastrointestinal microbiome (GIM), particularly the present probiotics, plays a vital role in the host immune system by mediating host protective immunity and acting as an immune regulator. Bacteriocins possess numerous health benefits and exhibit antagonistic activity against enteric pathogens and immunobiotics, thereby inhibiting viral infections. Moreover, disrupting the homeostasis of the GIM/host immune system negatively affects viral immunity. The interactions between bacteriocins and infectious viruses, particularly in COVID-19, through improved host immunity and physiology are complex and have not yet been studied, although several studies have proven that bacteriocins influence the outcomes of viral infections. However, the complex transmission to the affected sites and siRNA defense against nuclease digestion lead to challenging clinical trials. Additionally, bacteriocins are well known for their biofunctional properties and underlying mechanisms in the treatment of bacterial and fungal infections. However, few studies have shown the role of probiotics-derived bacteriocin against viral infections. Thus, based on the results of the previous studies, this review lays out a road map for future studies on bacteriocins for treating viral infections.
摘要:
病毒感染是严重的主要原因,全球致命疾病。最近,这些感染由于苛刻的上下文环境而增加,如环境变化,人口和产品分销的增加,人口快速变化,和新病毒的爆发,包括COVID-19疫情。影响病毒免疫的内部变量与这些外部原因一起受到关注,以避免此类新型病毒爆发。胃肠道微生物组(GIM),特别是目前的益生菌,通过介导宿主保护性免疫和充当免疫调节剂,在宿主免疫系统中起着至关重要的作用。细菌素具有许多健康益处,并表现出对肠道病原体和免疫生物的拮抗活性,从而抑制病毒感染。此外,破坏GIM/宿主免疫系统的稳态对病毒免疫产生负面影响。细菌素和感染性病毒之间的相互作用,特别是在COVID-19中,通过改善宿主免疫力和生理机能是复杂的,尚未研究,尽管有几项研究证明细菌素影响病毒感染的结局。然而,复杂的传递到受影响的位点和siRNA防御核酸酶消化导致具有挑战性的临床试验。此外,细菌素的生物功能特性和治疗细菌和真菌感染的潜在机制是众所周知的。然而,很少有研究表明益生菌来源的细菌素对抗病毒感染的作用。因此,根据以前的研究结果,这篇综述为细菌素治疗病毒感染的未来研究提供了路线图。